<code id='ECBD541F5E'></code><style id='ECBD541F5E'></style>
    • <acronym id='ECBD541F5E'></acronym>
      <center id='ECBD541F5E'><center id='ECBD541F5E'><tfoot id='ECBD541F5E'></tfoot></center><abbr id='ECBD541F5E'><dir id='ECBD541F5E'><tfoot id='ECBD541F5E'></tfoot><noframes id='ECBD541F5E'>

    • <optgroup id='ECBD541F5E'><strike id='ECBD541F5E'><sup id='ECBD541F5E'></sup></strike><code id='ECBD541F5E'></code></optgroup>
        1. <b id='ECBD541F5E'><label id='ECBD541F5E'><select id='ECBD541F5E'><dt id='ECBD541F5E'><span id='ECBD541F5E'></span></dt></select></label></b><u id='ECBD541F5E'></u>
          <i id='ECBD541F5E'><strike id='ECBD541F5E'><tt id='ECBD541F5E'><pre id='ECBD541F5E'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:6
          Astrazeneca office building -- health policy coverage from STAT
          AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

          WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

          The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

          advertisement

          AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Morphosys mixed study results for blood cancer drug
          Morphosys mixed study results for blood cancer drug

          AdobeLONDON—AnexperimentalbloodcancerdrugfromMorphoSyshititsprimarytargetinapivotaltrial,thecompanya

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          Readout Newsletter: Merck, J&J, and long Covid

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo